General Information of Drug (ID: DMERJ6V)

Drug Name
PHX-1766 Drug Info
Synonyms HCV protease inhibitors, Phenomix; Hepatitis c virus protease inhibitors, Phenomix; PHX-1176
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMERJ6V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TG-2349 DMZ571Y Hepatitis C virus infection 1E51.1 Phase 2 [3]
MK-6325 DMV8BI4 Hepatitis C virus infection 1E51.1 Phase 1 [4]
IDX-320 DMAYLS3 Hepatitis C virus infection 1E51.1 Discontinued in Phase 1/2 [5]
GS-9132 DMXB4T9 Hepatitis C virus infection 1E51.1 Discontinued in Phase 1/2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus Serine protease NS4A (HCV NS4A) TTRHUKY POLG_HCV1 Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029167)
2 Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antivir Ther. 2012;17(2):365-75.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp -sp Suzuki-Miyaura coupling and ring closing metathesis. Org Lett. 2015 Mar 20;17(6):1533-6.
5 Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.Antivir Ther.2012;17(4):633-42.